NCT04826562
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
Saint Michael's Medical Center·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Human Immunodeficiency Virus
- Drug/Device/Intervention
- Dolutegravir/Lamivudine
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Saint Michael's Medical Center
- Location
- Newark, United States of America
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Apr 01, 2021
- End date
- Jun 01, 2023
- Enrollment
- 40 participants
Primary outcome
Virologic Failure
Summary
An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy
 who are virological suppressed (HIV-1 50 copies/mL
ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesAsymptomatic human immunodeficiency virus [HIV] infection status
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04826562
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT04826562 through Pure Global AI's free database. This Phase 4 trial is sponsored by Saint Michael's Medical Center and is currently Not yet recruiting. The study focuses on Human Immunodeficiency Virus. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.